Human Trials

BeyondSpring’s Plinabulin demonstrates superior quality of life in phase 2/3 study in Neutropenia

BeyondSpring, a global biopharmaceutical company focused on the development of innovative cancer therapies, announced the results of its head-to-head clinical trial for Study BPI-2358-105, accepted as an abstract titled, “Quality of Life (QoL) in Advanced NSCLC Patients Treated with Docetaxel and with Either Plinabulin or Pegfilgrastim for the Prevention of Neutropenia.”

Cabotegravir, rilpivirine combo meets primary endpoint in HIV-1 phase 3 trial

ViiV Healthcare said that the injectable two-drug regimen of cabotegravir and rilpivirine succeeded in the ATLAS-2M phase 3 trial in adult patients with HIV-1 by meeting the primary endpoint.

AstraZeneca’s Farxiga meets primary endpoint in phase III heart failure study

AstraZeneca’s heart failure treatment Farxiga (dapagliflozin) has achieved the primary composite endpoint in the phase III DAPA-HF study.

Knopp begins phase 2 trial for oral dexpramipexole in eosinophilic asthma

Knopp Biosciences LLC today announced the start of Phase 2 dose-ranging clinical trial in moderate-to-severe eosinophilic asthma.

Lynparza plus bevacizumab meets primary endpoint in PAOLA-1 trial

AstraZeneca and MSD said that Lynparza (olaparib) in combination with standard-of-care (SoC) bevacizumab succeeded in a phase 3 trial in advanced ovarian cancer by meeting the primary endpoint.

Lilly announces superiority of Taltz versus TREMFYA in IXORA-R trial

Eli Lilly and Company (NYSE: LLY) announced today Taltz (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus TREMFYA (guselkumab) in people living with moderate to severe plaque psoriasis (PsO).

AstraZeneca’s Tagrisso meets secondary endpoint in phase III lung cancer study

AstraZeneca’s Tagrisso (osimertinib) has significantly improved overall survival (OS) in the patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer in the phase III Flaura trial.

Sesen Bio reports data update from phase 3 trial for high-risk non-muscle invasive bladder cancer

Sesen Bio, a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported updated, preliminary primary and secondary endpoint data from the Company’s Phase 3 VISTA trial further supporting the strong benefit-risk profile of Vicinium for the potential treatment of patients with high-risk, bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC).

Lynparza phase III PROfound trial in HRR mutation-selected metastatic castration-resistant prostate cancer met primary endpoint

AstraZeneca and MSD (known as Merck & Co., Inc. inside the US and Canada) announced positive results from the Phase III PROfound trial of Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer (mCRPC) who have a *homologous recombination repair gene mutation (HRRm) and have progressed on prior treatment with new hormonal anticancer treatments (e.g. enzalutamide and abiraterone).